TALVEY▼ (talquetamab), is approved for the treatment

Talquetamab is a bispecific T-cell engaging antibody that binds to CD3 The Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that

Related Keywords

United States , Ireland , Chicago , Illinois , American , Irish , Thorsten Giesecke , Patrick Hayden , European Haematology Association , Janssen Pharmaceutical Companies Of Johnson , Drug Administration , American Society Of Clinical Oncology , Janssen Sciences Ireland , European Commission , Janssen Pharmaceutical Companies , Consultant Haematologist , Clinical Oncology , Annual Meeting , Haematology Association , General Manager , Commercial Business , Confidence Interval , Not Estimable ,